Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 26, 2026HaematologicaOpen Access

Belumosudil achieves clinical response in chronic graft-versushost disease with varying organ-specific response kinetics: an analysis from the phase II ROCKstar trial

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAlaa AliLRLauren RotaKMKathy Marshall

Discussion

Loading...

Member takes

Overview

Randomized trial finds clinical responses in chronic graft-versus-host disease, suggesting targeted therapy may benefit patients.

Key Points

  • This research aims to evaluate the clinical effectiveness of belumosudil in patients with chronic graft-versus-host disease.
  • Phase II clinical trial
  • Assessment of organ-specific response kinetics
  • Data analysis from the ROCKstar trial
  • Significant clinical response observed in chronic graft-versus-host disease patients
  • Varied response kinetics across different organs
  • Potential implications for targeted therapeutic strategies

Cite This Study

Ali et al. (2026) studied this question.

synapsesocial.com/papers/6a65a36cd3aea3239cd76991https://doi.org/10.3324/haematol.2026.301043
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Response dynamics to belumosudil in chronic graft-versus-host disease: Characterizing late responses and organ-specific response expectations from the rockstar study2025
  2. 2Efficacy and safety of the ROCK2-inhibitor belumosudil for chronic gvhd treatment: Multicenter retrospective analysis of a large german-austrian cohort of the belumosudil managed-access program.2025
  3. 3ROCK 2 inhibition with belumosudil for the treatment of chronic graft-versus-host disease: a narrative review2025
  4. 4Investigating belumosudil in children with refractory moderate-to-severe chronic graft-versus-host disease: Design of a phase 1/2 study2025
  5. 5Belumosudil for Long‐Standing Refractory Chronic Graft‐Versus‐Host Disease: A Two‐Patient Case Report2026